(Q34557871)

3 August 2017

1 reference

title

Clinical pharmacokinetics of atomoxetine (English)

1 reference

3 August 2017

1 reference

John-Michael Sauer

1

1 reference

3 August 2017

Barbara J Ring

series ordinal

2

1 reference

3 August 2017

Jennifer W Witcher

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2005

1 reference

Clinical Pharmacokinetics

3 August 2017

published in

1 reference

3 August 2017

volume

44

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

571-590

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544060-00002

3 August 2017

exact match

0 references

cites work

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

12 December 2020

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

12 December 2020

Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

1 reference

12 December 2020

Overview and neurobiology of attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

1 reference

12 December 2020

Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

1 reference

12 December 2020

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

1 reference

12 December 2020

Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies

1 reference

12 December 2020

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

1 reference

12 December 2020

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children

1 reference

12 December 2020

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

1 reference

12 December 2020

An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients

1 reference

12 December 2020

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

12 December 2020

Extended-release methylphenidate (Ritalin LA).

1 reference

12 December 2020

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

1 reference

12 December 2020

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

12 December 2020

Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population

1 reference

12 December 2020

A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain

1 reference

12 December 2020

Tomoxetine and the stereoselectivity of drug action

1 reference

12 December 2020

Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism

1 reference

12 December 2020

Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.

1 reference

12 December 2020

Attention-deficit hyperactivity disorder and hyperkinetic disorder

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation

1 reference

12 December 2020

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Clinical pharmacology of tomoxetine, a potential antidepressant.

1 reference

12 December 2020

Pemoline-associated hepatic injury

1 reference

12 December 2020

Interactions of amphetamine analogs with human liver CYP2D6

1 reference

12 December 2020

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

1 reference

12 December 2020

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

1 reference

12 December 2020

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

12 December 2020

Management of ADHD in adults.

1 reference

12 December 2020

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

1 reference

12 December 2020

Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain

1 reference

12 December 2020

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

1 reference

12 December 2020

Cardiovascular effects of atomoxetine in children, adolescents, and adults

1 reference

12 December 2020

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

1 reference

12 December 2020

Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction.

1 reference

12 December 2020

Antidepressants in the treatment of attention-deficit/hyperactivity disorder

1 reference

12 December 2020

SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration

1 reference

12 December 2020

Antagonism by tomoxetine of the depletion of norepinephrine and epinephrine in rat brain by alpha-methyl-m-tyrosine.

1 reference

12 December 2020

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

1 reference

12 December 2020

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1 reference

12 December 2020

Addictiveness of central stimulants

1 reference

12 December 2020

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.

1 reference

12 December 2020

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

12 December 2020

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

12 December 2020

Psychiatric comorbidity in patients with attention deficit disorder: a controlled study.

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

1 reference

12 December 2020

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

12 December 2020

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

1 reference

12 December 2020

Molecular characterization of the dopamine transporter.

1 reference

12 December 2020

Followup studies on outcome of hyperactive children.

1 reference

12 December 2020

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

12 December 2020

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

1 reference

12 December 2020

Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder

1 reference

12 December 2020

Attention deficit disorder in adults

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

1 reference

12 December 2020

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1 reference

12 December 2020

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men

1 reference

12 December 2020

Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites

1 reference

12 December 2020

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

1 reference

12 December 2020

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

1 reference

12 December 2020

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

12 December 2020

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

1 reference

12 December 2020

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

1 reference

12 December 2020

10.2165/00003088-200544060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1041978940

0 references

1 reference